바이오테크 보도자료
-
- European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
- Takeda (TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage...
- 2023년 10월 19일
-
- Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
- Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of comb...
- 2023년 10월 18일
-
- Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
- Takeda (TSE:4502/NYSE:TAK ) today announced that, on October 17, 2023 (IST), it agreed with the Irish Revenue Commissioners (“Irish Revenue”) to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc (“S...
- 2023년 10월 18일
-
- Neu REFIX β-glucan reduces muscle fibrosis in Duchenne muscular dystrophy MDX mice, in joint research with Dr. Yoshitsugu Aoki, NCNP, Tokyo, Japan.
- Skeletal muscle fibrosis which leads to locomotor dysfunction in Duchenne Muscular Dystrophy (DMD) could be significantly reduced by oral consumption of Neu-REFIX beta 1,3-1,6 glucans alone for 45 days without any other drugs, in MDX mice model of...
- 2023년 10월 18일
-
- Merck to Present Latest Research from Oncology Portfolio at ESMO 2023
- Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be ...
- 2023년 10월 16일
-
- Medisca Takes Additional Steps to Protect Its Innovative Technologies
- Medisca has taken another step in protecting the strategic research and development (R&D) investments made decades ago that ultimately led to the industry-leading Medisca MAZ® mixer. The Medisca MAZ mixer provides an efficient, uniform, and high-q...
- 2023년 10월 15일
-
- UAE Calls for Global Consensus on AI Governance
- The UAE’s AI minister on Wednesday urged countries to come to a consensus on AI governance sooner than it came to the Paris Agreement, which took years to take shape and come into force. His Excellency Omar Al Olama, UAE Minister of State for Arti...
- 2023년 10월 15일
-
- Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) confirmed its initial negative opinion on the Marketing A...
- 2023년 10월 15일
-
- AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge
- AstraZeneca announced today eight winners of the 2023 R&D Postdoctoral Challenge and agreed to fund their postdoctoral positions at one of the Company’s strategic R&D centres in either Cambridge, UK, Gaithersburg or Boston, US or Gothenburg, Swede...
- 2023년 10월 13일
-
- SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers
- GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE), a Virginia, U.S.-based company, to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibro...
- 2023년 10월 12일
전시회
